Captrust Financial Advisors Global Blood Therapeutics, Inc. Transaction History

Captrust Financial Advisors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$22.3 - $37.39 $1,248 - $2,093	-56 Reduced 34.15%	108 $3,000
Q2 2022 Aug 16, 2022	SELL	$22.3 - $37.39 $2,163 - $3,626	-97 Reduced 37.16%	164 $5,000
Q1 2022 May 16, 2022	SELL	$25.68 - $35.59 $21,699 - $30,073	-845 Reduced 76.4%	261 $9,000
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $3,585 - $5,797	144 Added 14.97%	1,106 $32,000
Q3 2021 Nov 16, 2021	BUY	$25.48 - $37.34 $2,446 - $3,584	96 Added 11.09%	962 $25,000
Q2 2021 Aug 16, 2021	SELL	$32.46 - $43.42 $584 - $781	-18 Reduced 2.04%	866 $30,000
Q1 2021 May 17, 2021	BUY	$38.94 - $50.85 $24,103 - $31,476	619 Added 233.58%	884 $36,000
Q4 2020 Feb 16, 2021	BUY	$37.65 - $63.77 $564 - $956	15 Added 6.0%	265 $11,000
Q2 2020 Aug 14, 2020	BUY	$48.73 - $81.82 $12,182 - $20,455	250 New	250 $18,000
Q4 2019 Feb 14, 2020	SELL	$45.7 - $81.86 $36,788 - $65,897	-805 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$45.35 - $57.91 $272 - $347	6 Added 0.75%	805 $39,000
Q2 2019 Aug 13, 2019	BUY	$52.6 - $63.29 $42,027 - $50,568	799 New	799 $42,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.